Corcept Therapeutics
CORT
58 hedge funds and large institutions have $56.7M invested in Corcept Therapeutics in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
4% more funds holding
Funds holding: 56 → 58 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $62.8M → $56.7M (-$6.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$308K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$141K |
| 3 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$88.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$77.9K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.14M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$313K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$281K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$80.6K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$72K |
CORT Hedge Fund Activity: Q3 2013 in Review
58 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2013, worth a combined $56.7M — down 9.6% from $62.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CORT positions and 2 closed out — a net gain of 2 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $308K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $1.14M sold.
- 58 institutional investors held Corcept Therapeutics (CORT) as of Q3 2013, up from 56 in Q2 2013.
- Funds reported $56.7M of Corcept Therapeutics stock for Q3 2013, down 9.6% quarter-over-quarter.
- 4 funds opened new Corcept Therapeutics positions in Q3 2013 and 2 closed out, a net change of +2 holders.
- The largest Corcept Therapeutics buyer in Q3 2013 was BlackRock Fund Advisors, an estimated $308K added.
- The largest Corcept Therapeutics seller in Q3 2013 was Adage Capital Partners, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2013.